Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

terminated133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

NCT04296838
unknownnot_applicable

Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy

NCT02911311
unknown

Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases

NCT03128463

Clinical Trials (3)

Showing 3 of 3 trials
NCT04296838Phase 2

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

Terminated
NCT02911311Not Applicable

Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy

Unknown
NCT03128463

Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3